A Phase II Evaluation of Lapatinib (GW572016) (NCI-Supplied Agent, NSC 727989, IND 70,252) in the Treatment of Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma.

Trial Profile

A Phase II Evaluation of Lapatinib (GW572016) (NCI-Supplied Agent, NSC 727989, IND 70,252) in the Treatment of Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Jan 2013

At a glance

  • Drugs Lapatinib (Primary)
  • Indications Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 03 Mar 2011 Actual end date (Mar 2011) added as reported by ClinicalTrials.gov.
    • 03 Mar 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 06 Jun 2007 Status changed from suspended to in progress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top